NEDD4L and neoplasm: On the contrary, NEDD4L, in the presence of its chaperone protein14-3-3, targets HlF-1a for poly-ubiquitination and subsequent proteasome-mediated degradation, enhancing the anti-tumor effect of bevacizumab in colorectal cancer [30].